EC clears $17 billion acquisition of Hospira by Pfizer

The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.

A CRA team advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.

For more details, please see the Commission’s press release.